United Therapeutics (UTHR) Tops Q4 EPS Views

United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $3.68, $1.13 better than the analyst estimate of $2.55. Revenue for the quarter came in at $404.9 million versus the consensus estimate of $388.29 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.

You May Also Be Interested In

• H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
• Mount Logan Capital Inc. (MLCI) Reports Q2 Loss of $0.37
• Transact Technologies (TACT) Tops Q2 EPS by 1c